Advanced training: workshop during Focus 2019
Optimising patient management in IBD:
PANTS study outcomes and new perspectives for Therapeutic Drug Monitoring
Speakers: Tariq Ahmad, Rachel Nice & Mandy Perry, The Royal Devon and Exeter NHS Foundation Trust
Glasgow, Scottish Event Campus, May 2, 2019, 1:20 – 2:00 p. m.
Together with Biohit Healthcare, UK, Immundiagnostik invites to this gastroenterological workshop during the Focus conference 2019 in Glasgow.
The “Personalised Anti-TNF Therapy in Crohn’s Disease Study” (PANTS) is a prospective, observational, multicenter study with the aim to investigate the clinical, serological, and genetic factors that determine primary non-response, loss of response and anti-drug reaction in the patients when treated with infliximab or adalimumab.
Patients with inflammatory bowel disease receiving a biological therapy need to be reviewed to find good decisions whether to continue, switch or stop a therapy. Often the decision is made based on review of symptoms, disease history, and investigations. The aim of PANTS is to investigate whether therapeutic drug monitoring of infliximab (IFX) or adalimumab (ADA) trough levels and total anti-drug antibodies should, can or must influence decision making.
The conclusion at this stage of the study: basing decisions on therapeutic drug monitoring, rather than clinical acumen alone, led to a change in almost one-third of decisions made, offering considerable cost savings and reducing exposure to potentially toxic therapies. Routine therapeutic drug monitoring should therefore be considered an integral part of annual biologics assessment.
In this workshop you learn about the clinical background of PANTS, specials and algorithms in treatment and therapy monitoring with the biologicals IFX and ADA. Sophisticated know how about the biochemistry of therapy monitoring in the analytic laboratory complements this session.
• Tariq Ahmad is a Consultant Gastroenterologist to the Royal Devon and Exeter and Honorary Senior Lecturer at the University of Exeter medical school. He is a principal investigator of the UK IBD Genetic consortium and is the chief investigator of several nationwide NIHR portfolio studies including PANTS.
• Rachel Nice is a Senior Biomedical Scientist in the Blood Sciences Department at the Royal Devon and Exeter NHS Foundation Trust (RD&E), Exeter, UK. There she is responsible for running the clinical service for biologic drug monitoring of both clinical and research study samples including the PANTS study.
• Mandy Perry is a Senior Clinical Biochemist in the Blood Sciences Department at the Royal Devon and Exeter NHS Foundation Trust (RD&E), Exeter, UK. There she has established the clinical service for anti-TNFα monitoring for analysis of both clinical and PANTS study samples.